^{1Utility of plasma GFAP as a biomarker for Alzheimer's disease: A systematic review and meta-analysis2024 · Alzheimer's & Dementia · DOI 10.1002/alz.13445Open reference 2Astrocyte activation and GFAP elevation in Alzheimer's disease: Evidence from human studies and animal models2023 · Prog Neuropsychopharmacol Biol Psychiatry · DOI 10.1016/j.pnpbp.2023.110638Open reference 3Plasma GFAP predicts progression in Alzheimer's disease2023 · Nat Aging · DOI 10.1038/s43587-023-00398-xOpen reference 4GFAP as a marker of astrocyte reactivity in neurodegenerative diseases2023 · Acta Neuropathol Commun · DOI 10.1186/s40478-023-01552-7Open reference 5The role of astrocytes in Alzheimer's disease: From physiology to pathology2024 · Neurobiol Dis · DOI 10.1016/j.nbd.2024.105423Open reference 6Diagnostic accuracy of blood GFAP for Alzheimer's disease: A systematic review and meta-analysis2024 · J Gerontol A Biol Sci Med Sci · DOI 10.1093/gerona/glae053Open reference}

GFAP (Glial Fibrillary Acidic Protein)
Gene	[GFAP](/entities/gfap)
UniProt	P14136
PDB Structures	3TQ7 (rod domain fragment)
Molecular Weight	~50 kDa
Localization	Cytoplasm (cytoskeletal intermediate filament)
Protein Family	Type III intermediate filament protein
Diseases	[Alzheimer's Disease](/diseases/alzheimers), [Alexander Disease](/diseases/alexander-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), [Multiple Sclerosis](/diseases/multiple-sclerosis)
Associated Diseases	ALEXANDER_DISEASE, ALS, ALZHEIMER, ALZHEIMER'S, ALZHEIMER'S DISEASE
SciDEX Hypotheses	GFAP-Positive Reactive Astrocyte Subtype...
KG Connections	1504 edges

GFAP (Glial Fibrillary Acidic Protein)

Introduction

Gfap (Glial Fibrillary Acidic Protein) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

glial-fibrillary-acidic-protein (GFAP) is a ~50 kDa type III intermediate filament protein that serves as the principal cytoskeletal component of astrocytes in the central nervous system (CNS). Encoded by the glial-fibrillary-acidic-protein gene on chromosome 17q21.31, gfap is the canonical marker for astrocyte identification and has been used to study reactive-astrogliosis for over five decades since its initial characterization in 1971 (Eng et al., 1971).

In the past decade, GFAP has undergone a remarkable transformation from a histological marker to one of the most promising blood-based biomarkers for alzheimers and neurodegeneration. Plasma GFAP levels are elevated up to 10 years before symptom onset in individuals destined to develop AD, and higher levels predict faster cognitive decline, particularly among those with high brain amyloid burden (Benedet et al., 2023). The 2025 updated NIA-AA diagnostic criteria now include GFAP as a recognized biomarker for reactive astrogliosis in the AD continuum (Pan et al., 2025).

Beyond its biomarker role, gain-of-function mutations in GFAP cause alexander-disease, a rare leukodystrophy characterized by GFAP aggregation into Rosenthal fibers and severe astrocyte dysfunction, demonstrating the critical importance of GFAP homeostasis for brain health.

---

Structure

Domain Architecture

GFAP follows the conserved tripartite domain organization of type III intermediate filament proteins (Hol & Bhatt, 2015):

1. Head domain (N-terminal): Approximately 68 residues; intrinsically disordered; GFAP has the smallest head domain among type III IFs. Contains phosphorylation sites (Thr-7, Ser-8, Ser-13, Ser-34, Ser-38) that regulate filament assembly and disassembly

2. Rod domain (central): ~310 residues organized into four α-helical coiled-coil segments (1A, 1B, 2A, 2B) separated by linker regions. The rod domain mediates parallel coiled-coil dimerization with another GFAP monomer

3. Tail domain (C-terminal): ~61 residues; contains the highly conserved IF consensus motif; extends from filament surface and participates in inter-filament interactions

Assembly Hierarchy

GFAP assembly proceeds through a well-defined hierarchy:

• Dimers: Two GFAP monomers align in parallel, with their rod domains forming a coiled-coil

• Tetramers: Two dimers associate in an antiparallel, half-staggered arrangement — the basic soluble subunit

• Unit-length filaments (ULFs): ~8 tetramers associate laterally

• Mature filaments: ULFs anneal longitudinally and compact radially to form ~10 nm diameter filaments

Isoforms

At least 10 GFAP isoforms are generated by alternative splicing:

Isoform	Description	Significance
GFAPα	Full-length canonical isoform (432 aa)	Most abundant; constitutes the bulk of astrocytic IF network
GFAPδ/ε	Alternative C-terminal tail (exon 7a)	Enriched in subventricular zone and hippocampal neurogenic niches
GFAPκ	Alternative C-terminal (intron 7 retention)	Expressed in adult human brain at low levels

The ratio of GFAPδ to GFAPα modulates filament network properties and may be altered in AD and aging.

---

Normal Function

Astrocyte Cytoskeleton

GFAP provides structural rigidity and mechanical strength to astrocytes, enabling them to maintain their complex stellate morphology with numerous fine processes (Middeldorp & Hol, 2011):

• Forms the major cytoskeletal network in mature astrocytes, often co-assembling with vimentin in reactive states

• Maintains cell shape and mechanical integrity of astrocytic endfeet at the blood-brain-barrier and perivascular spaces

• Provides structural support for astrocyte processes that ensheath synapses and regulate the tripartite synapse

Signaling and Intracellular Functions

Beyond structural roles, GFAP participates in several signaling functions:

• Intracellular trafficking: Scaffolds for vesicle transport and organelle positioning within astrocyte processes

• Notch signaling regulation: GFAP network integrity modulates Notch pathway activity in neural progenitors

• autophagy: GFAP interacts with LAMP2A, regulating chaperone-mediated autophagy in astrocytes

• mtor-neurodegeneration signaling: Disrupted GFAP network (as in Alexander disease) activates stress kinases and mtor-neurodegeneration

Brain Expression Pattern

GFAP expression varies across brain regions and astrocyte subtypes:

• Highest expression in white matter fibrous astrocytes and Bergmann glia of the cerebellum

• Lower expression in gray matter protoplasmic astrocytes

• Virtually absent in oligodendrocytes, neurons, and microglia/cell-types/microglia under normal conditions

• Also expressed in non-myelinating schwann-cells, enteric glial cells, and some stem cell populations

---

Role in Disease

Alzheimer’s Disease — Biomarker

Plasma GFAP has emerged as one of the most clinically valuable blood biomarkers for AD:

Diagnostic accuracy: A 2023 systematic review and meta-analysis reported that plasma GFAP distinguishes AD dementia from cognitively normal controls with pooled sensitivity of 80% and specificity of 83% (Garduño-Salinas et al., 2023).

Preclinical detection: Plasma GFAP is elevated 10+ years before cognitive symptom onset in individuals with brain amyloid positivity. In the TRIAD cohort, GFAP increases were among the earliest biomarker changes in the AD cascade, appearing before nfl-protein or p-tau217 elevations (Benedet et al., 2023).

Specificity for amyloid pathology: Unlike neurofilament-light (which rises in multiple neurodegenerative conditions), plasma GFAP shows relative specificity for amyloid-positive neurodegeneration. It correlates strongly with amyloid PET positivity and may reflect the astrocytic response to early Aβ pathology.

Clinical trial enrichment: A 2025 study demonstrated that using plasma GFAP alongside amyloid-beta PET for trial enrichment in preclinical AD reduces required sample sizes and costs while selecting individuals at earlier disease stages (Bellaver et al., 2025).

Pathological correlation: Regional brain GFAP levels in postmortem AD tissue correlate with local amyloid plaque burden and tau] tangle] density, particularly in the frontal and temporal cortex (Garrick et al., 2024).

Alzheimer’s Disease — Astrogliosis

In AD brains, GFAP is dramatically upregulated in reactive-astrocytes-a2 surrounding [amyloid plaques]:

• Reactive astrocytes increase GFAP expression 3–5 fold and extend hypertrophied processes toward amyloid-beta deposits

• This astrogliosis is thought to represent both a protective response (plaque encapsulation, amyloid-beta phagocytosis) and a toxic response (release of pro-inflammatory cytokines, complement components)

• GFAP release from reactive and damaged astrocytes into CSF and blood provides the biochemical basis for its biomarker utility

Alexander Disease

alexander-disease is caused by dominant gain-of-function mutations in the GFAP gene, making it the only known human disease caused by an intermediate filament mutation in astrocytes (Brenner et al., 2001):

• Over 100 missense mutations identified; hotspots at R79, R88, R239, and R416

• Mutant GFAP aggregates into characteristic Rosenthal fibers — dense, eosinophilic cytoplasmic inclusions containing GFAP, αB-crystallin, hsp27, and ubiquitin

• Rosenthal fibers impair astrocyte function, trigger oxidative-stress, activate stat3 signaling, and disrupt white matter integrity

• Clinical presentations range from infantile (severe macrocephaly, seizures, leukoencephalopathy) to adult (bulbar symptoms, ataxia, demyelination

Other Neurodegenerative Diseases

GFAP is elevated in CSF and/or plasma in multiple neurodegenerative conditions, reflecting underlying astrogliosis:

• parkinsons: Elevated plasma GFAP, particularly in PD dementia and PD with amyloid co-pathology

• als: CSF GFAP elevated; correlates with disease progression rate

• multiple-sclerosis: Serum GFAP peaks during acute relapses and correlates with disability progression

• traumatic-brain-injury: Plasma GFAP is FDA-cleared as a TBI diagnostic biomarker (Banyan BTI™)

• cte: Elevated GFAP in peri-vascular astrocytes at sulcal depths

---

Therapeutic Implications

GFAP as Therapeutic Target

Because GFAP overaccumulation drives Alexander disease pathology, several strategies to reduce GFAP levels are under development:

• Antisense oligonucleotides (ASOs): Intrathecal ASOs targeting GFAP mRNA reduce Rosenthal fiber formation and reverse astrocyte dysfunction in Alexander disease mouse models

• STAT3 inhibition: STAT3 drives GFAP transcription in reactive astrocytes; inhibitors may dampen pathological GFAP upregulation

• autophagy enhancement: Promoting autophagic clearance of aggregated GFAP may reduce Rosenthal fiber burden

GFAP as Therapeutic Monitoring Biomarker

Plasma GFAP is increasingly used as a pharmacodynamic biomarker in clinical trials:

• Anti-amyloid therapies (lecanemab, aducanumab reduce plasma GFAP levels over time, likely reflecting reduced astrogliosis as amyloid is cleared

• GFAP trajectories may help identify early treatment responders

• Serial GFAP measurements could supplement cognitive endpoints in prevention trials

---

See Also

• [Proteins Index

• [Genes Index

• [Mechanisms Index

External Links

• NCBI Gene: GFAP

• UniProt: P14136

• Allen Brain Atlas: GFAP Expression

Background

The study of Gfap (Glial Fibrillary Acidic Protein) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources